CD274 and non-small cell lung carcinoma: Anti-PD-L1 antibody atezolizumab is suggested for treatment of urothelial cancer 22, 32 and NSCLC 6, 33, and anti-PD-L1 antibodies avelumab and durvalumab can be used to treat urothelial cancer34, 35.